Exciting combination of product solutions will create a
leading neurodiagnostic and neuromonitoring portfolio supported by
an organization of knowledgeable and passionate
experts.
MIDDLETON, Wis., Dec. 2, 2022 /PRNewswire/ -- Natus
Medical Incorporated (the "Company" or "Natus"), a leading
provider of medical device solutions focused on the screening,
diagnosis and treatment of central nervous and sensory system
disorders, has entered into a definitive agreement to acquire
Micromed Holding SAS ("Micromed Group" or "Micromed"), a global
provider of neurophysiology solutions. The transaction is expected
to close in early 2023, subject to the receipt of regulatory
approvals.
The acquisition of Micromed will be the first transaction by
Natus since being acquired by the ArchiMed Group ("ARCHIMED") in
July of this year. "We are pleased to make this first
growth-oriented investment as an ARCHIMED portfolio company," said
Thomas J. Sullivan, Natus Chief
Executive Officer. "The breadth and depth of clinical expertise in
Natus and Micromed will enable us to bring exciting innovation to
our neuroscience customers and their patients around the globe,"
Together, Natus and Micromed will provide customers with a
best-in-class portfolio of neurodiagnostic and neuromonitoring
solutions. A Natus legacy of over 85 years of neurodiagnostic
leadership including brands such as
NeuroWorks®/SleepWorks™, Natus
Quantum®, Grass ®, Nicolet®,
Xltek®, Embla®,
Dantec™ TECA® and others will
combine with the complete line of Micromed solutions including
BRAIN
QUICK®/MYOQUICK®,
NEUROWERK®, SleepRT® and MOBERG. The products
will also enable a strong platform for new product development in
electroencephalography (EEG), polysomnography (PSG),
electromyography (EMG), and intensive care unit (ICU) monitoring
through the integration of the best aspects of both product
portfolios, including backward compatibility.
"Joining the forces of the Natus and Micromed teams with their
collective knowledge and passion for neurodiagnostics and
neurocritical care, will result in both a more comprehensive
product offering and an unrivaled global service and support
structure for the benefit of our customers," said Austin Noll, Natus
President and leader of Natus
Neuro. Mr. Noll added "the management of our new Natus Neuro
Team will work closely with Micromed management to build upon the
Micromed momentum in the European Epilepsy market and the emerging
presence of Moberg in the ICU."
About Natus - www.natus.com -Natus delivers innovative
and trusted solutions to screen, diagnose, and treat disorders
affecting the brain, neural pathways, and eight sensory nervous
systems to advance the standard of care and improve patient
outcomes and quality of life. The Company offers hardware, advanced
software and algorithms, and consumables that provide stimulus,
acquire and monitor physiological signals, and capture the body's
response. With sales in over 100 countries, Natus is a leader in
neurodiagnostics, pediatric retinal imaging, and infant hearing
screening, as well as a leading company in hearing assessment,
hearing instrument fitting, balance, and intracranial pressure
monitoring. The Natus product portfolio represents a
heritage of innovation and leadership. Natus brands have been
setting the standard for patient care for over 85 years. Our
products are trusted by medical professionals in university medical
centers, hospitals, private practices, clinics and research
laboratories around the world. Natus supports our customers'
evolving needs with clinical expertise, continuing education, and
outstanding technical service.
About Micromed – Founded in 1982, Micromed is a medical
device company delivering solutions in Neurophysiology to over 78
countries worldwide. Partnering with hospitals, sleep labs and
research centers on a global scale, Micromed manufactures and
markets high quality, cost effective and clinically relevant
neurodiagnostic hardware and software to neurologists, clinicians
and researchers for use on adult and pediatric patients. The
Micromed product portfolio ranges from Routine, Ambulatory and
Video EEG to electrocorticography (ECoG),
stereoelectroencephalography (SEEG) , PSG, evoked potentials (EP),
EMG and ICU multimodal monitoring solutions for clinical and
research.
About ARCHIMED - www.archimed.group - With
offices in the US and Europe,
ARCHIMED is a leading investment firm focused exclusively on
healthcare industries. Its mix of operational, medical, scientific
and financial expertise allows ARCHIMED to serve as both a
strategic and financial partner to North American and European
healthcare businesses. Prioritized areas of focus include
Biopharmaceutical Products & Services, Life Science Tools,
Medical Devices & Technologies, In Vitro Diagnostics,
Healthcare IT and Consumer Health. ARCHIMED helps partners
internationalize, acquire, innovate and expand their products and
services. Over the last twenty years, ARCHIMED's leadership team
has directly managed and invested in over eighty small- to
large-size healthcare companies globally, representing over €50
billion of combined value. ARCHIMED manages €6 billion across its
various funds. Since inception, ARCHIMED has been a committed
Impact investor, both directly and through its EURÊKA
Foundation.
Contacts:
Natus Medical Incorporated
InvestorRelations@Natus.com
ARCHIMED
France: Stéphanie du Ché,
stephanie.duche@archimed.group, +33 (0)6 16 36 11 08;
International: David Lanchner,
dlanchner@lanchner.com, +33 (0)6 33 43 50 76
View original
content:https://www.prnewswire.co.uk/news-releases/natus-medical-incorporated-to-acquire-micromed-holding-sas-301692643.html